<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164999">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02156297</url>
  </required_header>
  <id_info>
    <org_study_id>SZ3201</org_study_id>
    <nct_id>NCT02156297</nct_id>
  </id_info>
  <brief_title>Sorafenib to Treat FLT3-ITD AML</brief_title>
  <official_title>Sorafenib to Treat AML Patients With FLT3-ITD Mutation: a Non-interventional Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a prospective, non-interventional, open-label study, in order to observe the safety
      and response in FLT3-ITD mutation positive AML patients who receiving sorafenib as
      induction, consolidation, salvage, maintenance or alleviative treatment. The duration of the
      study from June 2014 through May 2019, with the  recruitment duration from June 2014 to May
      2017. The inclusion criteria is:

        1. Definitely diagnosed as AML

        2. FLT3-ITD mutation has been confirmed

        3. Accepting the prescription of sorafenib
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Progress-Free Survival</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia-Free Survival</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to the onset of sorafenib resistance</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>FLT3-ITD Mutation</condition>
  <arm_group>
    <arm_group_label>Induction Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Consolidation Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Salvage Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Alleviatitive Group</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who diagnosed as AML with FLT3-ITD mutation and accepting the prescription of
        sorafenib.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Definitely diagnosed as AML

          -  FLT3-ITD mutation has been confirmed

          -  Accepting the prescription of sorafenib

        Exclusion Criteria:

          -  Can not take drugs orally

          -  Can not follow the doctors' advices

          -  Other reasons that investigators considered as contra-indications for this study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>May 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
